CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled / 17 target
Drug / intervention
Tavo +2 moredrug
Likely dose
Tavo 0.1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04526730
NCT04526730Phase 2CompletedUpdate Overdue (0.3/mo)Completion was 27mo ago

Neoadjuvant Immunotherapy With Intratumoral Tavokinogene Telseplasmid (Tavo) Plus Electroporation in Combination With Intravenous Nivolumab in Patients With Operable Locally- Regionally Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Aug 26, 2020·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Tavo, Nivolumab, and 1 other intervention for Melanoma. Completed, enrolled 17 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological diagnosis of operable locally-regionally advanced melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 26, 2020
Enrollment StartDec 22, 2020
Primary CompletionMar 26, 2024
Study CompletionMay 22, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.9 years ago

Arms & Interventions

Neoadjuvant Treatmentexperimental

Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion). Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist. Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase.

Drug: TavoDrug: NivolumabDevice: OncoSec Medical Electroporation Therapy System

Interventions

Tavodrug

Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3

Nivolumabdrug

Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions

OncoSec Medical Electroporation Therapy Systemdevice

The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end. Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence.